Lead Product(s) : Tibulizumab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zura Bio Starts Global Phase 2 TibuSHIELD Study for Tibulizumab in HS Patients
Details : ZB-106 (tibulizumab) is a dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways being investigated in adults with moderate to severe hidradenitis suppurativa (HS).
Product Name : ZB-106
Product Type : Antibody
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : Tibulizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tibulizumab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zura Bio Launches Phase 2 TibuSURE Study for Tibulizumab in Systemic Sclerosis
Details : ZB-106 (tibulizumab) is an humanized, tetravalent bispecific dual-antagonist antibody engineered to bind to and neutralize both IL-17A and BAFF, being investigated in systemic sclerosis (SSc).
Product Name : ZB-106
Product Type : Antibody
Upfront Cash : Inapplicable
December 23, 2024
Lead Product(s) : Tibulizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STS-01
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Soterios Pharma Reports Positive Phase II Results for STS-01 in Alopecia Areata
Details : STS-01 is a topical formulation which works by modulating cytokines, it is under development for the treatment of mild / moderate alopecia areata.
Product Name : STS-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : STS-01
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tuvatexib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VDA-1102 (tuvatexib) is a novel Hexokinase 2 modulator small molecule drug which is under phase 2 clinical development for the treatment of actinic keratosis.
Product Name : VDA-1102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2023
Lead Product(s) : Tuvatexib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EVO101
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : EQT Life Sciences
Deal Size : $50.0 million
Deal Type : Series B Financing
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Details : The capital raised will support Evommune’s three prioritised pipeline programs targeting highly prevalent inflammatory diseases, including EVO101, a novel small molecule inhibitor of the IRAK4.
Product Name : EVO101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 27, 2023
Lead Product(s) : EVO101
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : EQT Life Sciences
Deal Size : $50.0 million
Deal Type : Series B Financing
Lead Product(s) : STS-01
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Soterios Pharma completes Phase II Enrolment for STS-01 in Mild / Moderate (patchy) Alopecia Areata
Details : STS-01 is a cytokine modulator that modulates the inflammatory response and the proliferation of T-cells by disruption of the signalling pathways. It is under phase 2 clinical development for the treatment of mild / moderate (patchy) alopecia areata.
Product Name : STS-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2023
Lead Product(s) : STS-01
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonelokimab is a novel tri-specific Nanobody® targeting IL 17A and IL-17F that also has an extended half-life and enhanced biodistribution through engineered binding affinity to albumin.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonelokinab is a novel investigational IL-17 A/F Nanobody® that neutralizes both IL-17A and IL-17F. The trial met its primary endpoint based on Investigator's Global Assessment at week 12 with clinically meaningful and statistically significant results ...
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable